                         SEQUENCE LISTING

<110>  Eli Lilly and Company
       Zhang, Lianshan
       Alsina-Fernandez, Jorge

<120>  Selective VPAC2 Receptor Peptide Agonists

<130>  X17355 WO

<150>  US 60/743,365
<151>  2006-02-28

<160>  7     

<170>  PatentIn version 3.3

<210>  1
<211>  39
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Cyclic VPAC2 peptide receptor agonist P403


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  C6 acylation

<220>
<221>  MOD_RES
<222>  (10)..(10)
<223>  Methoxy

<220>
<221>  MOD_RES
<222>  (12)..(12)
<223>  Orn

<220>
<221>  MOD_RES
<222>  (15)..(15)
<223>  Aib

<220>
<221>  MOD_RES
<222>  (17)..(17)
<223>  Nle

<220>
<221>  MOD_RES
<222>  (21)..(21)
<223>  Orn

<220>
<221>  SITE
<222>  (21)..(25)
<223>  Lactam bridge

<220>
<221>  MOD_RES
<222>  (27)..(28)
<223>  Orn

<400>  1

His Ser Asp Ala Val Phe Thr Glu Asn Tyr Thr Xaa Leu Arg Xaa Gln 
1               5                   10                  15      


Xaa Ala Ala Lys Xaa Tyr Leu Asn Glu Leu Xaa Xaa Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Pro Ser 
        35                  


<210>  2
<211>  28
<212>  PRT
<213>  Homo sapiens

<400>  2

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gln 
1               5                   10                  15      


Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn 
            20                  25              


<210>  3
<211>  27
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MOD_RES
<222>  (27)..(27)
<223>  AMIDATION

<400>  3

His Ser Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln 
1               5                   10                  15      


Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu 
            20                  25          


<210>  4
<211>  37
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MOD_RES
<222>  (37)..(37)
<223>  AMIDATION

<400>  4

His Ser Asp Gly Ile Phe Thr Asp Ser Tyr Ser Arg Tyr Arg Lys Gln 
1               5                   10                  15      


Met Ala Val Lys Lys Tyr Leu Ala Ala Val Leu Gly Lys Arg Tyr Gln 
            20                  25                  30          


Arg Val Lys Asn Lys 
        35          


<210>  5
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: N-terminal modification

<400>  5

Ser Trp Cys Glu Pro Gly Trp Cys Arg 
1               5                   


<210>  6
<211>  39
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence: Reference peptide used for percentage 
       sequence identity calculations


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  C6 acylation

<220>
<221>  MOD_RES
<222>  (10)..(10)
<223>  Methoxy

<220>
<221>  MOD_RES
<222>  (17)..(17)
<223>  Nle

<220>
<221>  SITE
<222>  (21)..(25)
<223>  Lactam bridge

<400>  6

His Ser Asp Ala Val Phe Thr Glu Asn Tyr Thr Lys Leu Arg Lys Gln 
1               5                   10                  15      


Xaa Ala Ala Lys Lys Tyr Leu Asn Asp Leu Lys Lys Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Pro Ser 
        35                  


<210>  7
<211>  11
<212>  PRT
<213>  Heloderma suspectum

<400>  7

Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser 
1               5                   10      


